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esearch Challenges and Opportunities
iane L. Lucas, PHD,* Ricardo A. Brown, PHD,* Momtaz Wassef, PHD,† Thomas D. Giles, MD‡
ethesda, Maryland; and New Orleans, Louisiana
Excessive alcohol consumption has long been associated with cardiovascular disorders,
including cardiomyopathy, hypertension, coronary artery disease, and stroke. However, recent
evidence suggests that moderate alcohol intake can actually provide a measure of cardiopro-
tection, particularly against coronary heart disease and ischemia-reperfusion injury. To
explore the various dimensions of these opposing actions of alcohol, the National Institute on
Alcohol Abuse and Alcoholism and the National Heart, Lung, and Blood Institute sponsored
a state-of-the-art workshop on “Alcohol and the Cardiovascular System: Research Challenges
and Opportunities” in Bethesda, Maryland, in May 2003. Speakers discussed the following
topics: the epidemiology of alcohol and cardiovascular disease, clinical manifestations of
alcohol, genetics of alcohol and cardiovascular disease, mechanisms underlying the molecular
and cellular effects of alcohol, the application of new and emerging technology, and
translation from discovery to therapeutic modalities of treatment. The panel concluded that
future studies are needed to: 1) determine the role of genes and the environment in assessing
mechanisms underlying the benefits of alcohol use and cardiovascular disease risk; 2) define
the biological mechanisms underlying alcohol-induced peripheral vascular damage; 3) clarify
the role of genetic variation in alcohol-metabolizing enzymes, genetic susceptibility, and
pharmacogenomics in determining cardiovascular disease risk and effective treatment;
4) determine common mechanisms underlying alcohol-induced cardiovascular disease, such
as oxidative stress and inflammation; 5) assess the role of insulin resistance, blood clotting,
protein kinase C isoforms, and signal transduction mechanisms mediating alcohol’s beneficial
effects; and 6) explore the potential of stem cells in myocardial regeneration and repair in
hearts damaged by alcohol. (J Am Coll Cardiol 2005;45:1916–24) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.075College of Cardiology Foundation
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excessive alcohol intake is a major cause of toxic cardiomy-
pathy in the U.S. today, yet low-level ingestion of alcohol
ver long periods of time appears to afford a measure of
rotection to the heart and vasculature against disease. The
ational Institute on Alcohol Abuse and Alcoholism and
he National Heart, Lung, and Blood Institute convened a
tate-of-the-art workshop to discuss the complex interac-
ions between alcohol and the cardiovascular system. The
oals of the workshop were: to assess current information
egarding the population-wide risks and benefits of alcohol
onsumption with respect to cardiovascular morbidity and
ortality, to explore the etiologies of these relationships,
nd to chart a new course for future investigations into the
iological basis of alcohol’s effects on the cardiovascular
ystem. This state-of-the-art report summarizes the epide-
iology, genetics, and clinical manifestations of alcohol and
ardiovascular disease and presents new findings on the
ellular and molecular mechanisms underlying the medical
onsequences of alcohol. Recommendations for research
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aryland; and ‡Department of Medicine, Louisiana State University Health Sciences
enter, New Orleans, Louisiana.a
Manuscript received September 25, 2004; revised manuscript received February 9,
005, accepted February 22, 2005.hat may lead to new principles for the treatment and
revention of cardiovascular mortality associated with ex-
essive ethanol consumption are presented.
HE EPIDEMIOLOGY OF ALCOHOL
ONSUMPTION AND CARDIOVASCULAR DISEASE
oronary heart disease (CHD) is the most common form of
eart disease in the U.S. and affects approximately 13
illion Americans (1). Recent epidemiologic and clinical
vidence suggests that light-to-moderate alcohol consump-
ion is associated with a reduced risk for developing CHD
nd ischemic stroke (IS) (2). The relationship between
lcohol intake and the relative risk of developing CHD is a
- or U-shaped dose-response, where the risk is lower when
lcohol consumption is light-to-moderate and is high when
lcohol consumption is higher or absent altogether. “Mod-
rate drinking” is defined as no more than one drink/day for
omen and two drinks/day for men (U.S. Department of
ealth and Human Services/U.S. Department of Agricul-
ure Dietary Guidelines 2005). In the U.S., one drink is
sually considered to be 12 oz of beer, 5 oz of wine, or 1.5
unces of spirits. A standard drink contains 0.6 oz (15 g) of
thanol.
A meta-analysis of the relationship between moderate
lcohol intake and risk of developing CHD showed that,
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June 21, 2005:1916–24 Alcohol and the Cardiovascular Systemompared with abstention, moderate alcohol consumption
as much as 30 g/day) is causally related to a 20% to 45%
eduction in the risk of developing CHD (3). Prospective
tudies from several countries worldwide suggest that the
eneficial effects of moderate alcohol consumption are not
ependent on the type of beverage or pattern of consump-
ion (4,5). Thus, although red wine consumption was
hought to be important in the “French paradox,” it appears
hat it is the alcohol itself that confers the major benefit (6).
he “French paradox” refers to the low mortality rate from
schemic heart disease and cardiovascular diseases displayed
y French men despite a high level of risk factors, such as
holesterol, diabetes, hypertension, and a high intake of
aturated fat (7). Levels of alcohol intake in excess of 120
/day to 150 g/day significantly increase the risk of CHD,
ypertension, IS, and all-cause mortality (2). However,
any confounding factors, for example, socioeconomic
tatus, lifestyle variables, and the “sick quitter” effect, may
nfluence the relationship between alcohol and cardiovascu-
ar disease (8).
Mechanisms underlying the cardioprotective effects of
oderate alcohol consumption may be related to alcohol-
nduced changes in serum lipids, lipoproteins, blood clotting
roteins, platelets, inflammatory cytokines, and insulin re-
istance (9). Moderate alcohol consumption has been shown
o increase high-density lipoprotein cholesterol (HDL-C)
y approximately 30% and is believed to account for
pproximately 50% of the reduced risk of developing CHD
10). The proportion of reduced risk not accounted for by
ncreased HDL-C may be attributable to alcohol-induced
ncreased insulin sensitivity, lower levels of inflammatory
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ADH  alcohol dehydrogenase
ALDH  acetaldehyde dehydrogenase
Apo  apoliporotein
BT  blood thrombosis
CAD  coronary artery disease
CHD  coronary heart disease
DCM  dilated cardiomyopathy
FDC  familial dilated cardiomyopathy
HDL-C high-density lipoprotein cholesterol
HF  heart failure
IC  intermittent claudication
IDC  idiopathic dilated cardiomyopathy
IL  interleukin
IS  ischemic stroke
LDL-C  low-density lipoprotein cholesterol
MI  myocardial infarction
MSC  mesenchymal stem cells
NAD  nicotinamide adenine dinucleotide
NO  nitric oxide
PKC  protein kinase C
ROS  reactive oxygen species
SCD  sudden cardiac death
TF  tissue factorarkers such as interleukin (IL)-6, C-reactive protein, and cumor necrosis factor-alpha, constituents of beverages
ther than alcohol, and polymorphisms among alcohol-
etabolizing enzymes, which reduce toxic metabolites,
rimarily acetaldehyde (11,12). The pattern of alcohol
onsumption as it relates to clinical outcomes and changes
n cardiovascular risk has been examined in the Framingham
ohort (13), in which most adult men and women, approx-
mately 80% and 67%, respectively, consume alcohol. The
roportion of individuals consuming alcohol decreases with
ge, a trend that may relate to adverse clinical outcomes. A
4-year follow-up study of Framingham participants con-
uming 2 to 2.5 standard drinks/day showed that among
onsmokers, increasing alcohol intake decreased the inci-
ence of CHD, whereas among light smokers, a U-shaped
elationship was seen with increasing intake. In heavy
mokers, there was no association between alcohol intake
nd CHD.
The relationship between alcohol intake and heart
ailure (HF), IS, intermittent claudication (IC), and all-
ause mortality has been investigated. In a study separat-
ng nondrinkers, former drinkers, and current drinkers
ccording to the number of drinks consumed each day, there
as a decline in the crude incidence rates and HF risk from
ondrinkers to moderate consumers. From moderate to
eavy consumers, there is an upturn in the curve describing
he relative risk of developing HF in both men and women.
ata presented at the workshop and subsequently published
14) indicate little association between long-term moderate
lcohol consumption and atrial fibrillation, a risk factor for
troke, among participants in the Framingham Study. How-
ver, a significant increase in stroke risk was observed
mong both active and former drinkers consuming more
han three drinks/day.
The risk of IC in Framingham participants reveals a
teady decrease in incidence with increasing alcohol intake,
n effect that was more evident in men than in women and
ore strongly associated with wine and beer than with
pirits. All-cause mortality attributable to alcohol also was
nalyzed in Framingham participants. In each case, people
ho drank heavily had an increased mortality risk compared
ith moderate drinkers. The findings in this cohort suggest
hat moderate alcohol consumption is inversely associated
ith risk for CHD, congestive HF, and IC. This association
as been confirmed in a meta-analysis on all-cause mortality
ublished since the workshop, which demonstrated an inverse
ssociation between light-to-moderate drinking and total
all-cause) mortality (15). The resulting J-shaped curve,
ith the lowest mortality risk occurring at the level of one to
wo drinks/day, is caused primarily by the protective effects
f alcohol consumption on CHD. The relationship between
lcohol consumption and CHD has been the subject of
merican Heart Association/American College of Cardiol-
gy science advisories (16,17), which conclude that, in the
bsence of proof of causality, the use of alcohol as a
ardioprotective strategy is not recommended.
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Alcohol and the Cardiovascular System June 21, 2005:1916–24LCOHOL AND THE CARDIOVASCULAR
YSTEM: CLINICAL MANIFESTATIONS
or many decades, research has shown that atherosclerosis is
he principal contributor to the pathogenesis of myocardial
nd cerebral infarction and peripheral vascular disease. In
ddition to the role played by lipoproteins in atherogenesis,
xperimental and clinical studies have provided ample evi-
ence for the presence of ongoing inflammation in athero-
clerosis (18). Although there is no evidence of a direct
ffect of alcohol on inflammatory mediators influencing
ardiovascular disease and stroke, effects on surrogate end
oints have been demonstrated.
Atherosclerosis is a diffuse disease, and its presentation
aries depending upon the vascular bed in which it occurs.
n the coronaries, an acute clinical event occurs by the
nduction of plaque rupture in lipid-rich lesions. Plaque
upture leads to thrombus formation, partial or complete
cclusion of the arteries, unstable angina, myocardial infarc-
ion, and/or sudden death. Rupture of lipid-rich atheroscle-
otic lesions within the thoracic aorta is the cause of
diopathic or cryptogenic stroke. In comparison, atheroscle-
otic lesions within the carotid arteries are characteristically
brotic and stenotic. It is likely that the force of blood
gainst the arterial wall during systole produces dissection
etween the media and adventitia, causing an intramural
ematoma to open into the lumen, and subsequent throm-
otic stroke. Atherosclerotic lesions in the peripheral vas-
ulature and circulation are large and stenotic but usually do
ot rupture. Rather, blood from patients with peripheral
ascular disease who suddenly develop an occlusion has been
hown to have a clotting propensity or hypercoagulable state
19). Hypercholesterolemia, inflammation, and thrombosis
aused by a hypercoagulable state are part of the complex
tiology of the atherogenic process. The salutary effects of
oderate alcohol on coronary artery disease (CAD) are
ediated in part through HDL-C; however, components of
he inflammatory and thrombotic pathways, which are key
actors in atherogenesis, also are influenced by alcohol (18).
he clinical manifestations of moderate alcohol on several
ardiovascular outcomes are summarized in Figure 1.
High-density lipoprotein cholesterol has been shown to
rotect against atherosclerosis by influencing a number of
teps in the initiation and progression of the disease.
igh-density lipoprotein cholesterol inhibits low-density
ipoprotein cholesterol (LDL-C) oxidation, thus preventing
ptake by macrophages, foam cell formation, and apoptosis.igure 1. Clinical consequences of ethanol consumption. ADH  alcohol dehyd
isease; CV  cardiovascular; IL  interleukin.ransformation of macrophages to foam cells also is inhib-
ted by secretion of apolipoprotein E, which promotes
holesterol efflux to HDL-C (20). In addition, HDL-C
iminishes the formation of tissue factor (TF) and reduces
he levels of metalloproteinases. In summary, increased
evels of HDL-C seem to protect against the initiation of
he atherosclerotic process very early on in the cascade of
vents by protecting against LDL-C oxidation, promoting
he efflux of lipids and cholesterol from the lesion, decreas-
ng adhesion receptor expression, and protecting against
acrophage apoptosis with the attendant release of metal-
oproteinases and TF. Nevertheless, alcohol’s effects on the
omponents of these pathways and the processes they
egulate have not been studied.
Pathologic studies suggest that the development of
hrombus-mediated acute coronary/cerebral events depends
rincipally on plaque composition and vulnerability rather
han the severity of stenosis (21). Vulnerable plaques gen-
rally have thin fibrous caps and increased numbers of
nflammatory cells, the products of which likely influence
oth plaque composition and rupture. Recent studies show-
ng that ruptured plaques are highly enriched with a
etwork of neovessels have suggested the novel hypothesis
hat neovessels within vulnerable regions of atherosclerotic
esions may play a role in plaque disruption (22). Further-
ore, neovessels likely serve as a conduit for the entry of
onocytes, which are known to be involved in carotid
laque hemorrhage. The major source for medial and
ntimal neovessels is the vasa-vasorum in the adventitia.
ecent experimental studies have shown enhanced coronary
asa-vasorum accompanies CAD. Several studies have doc-
mented a complex interaction between neovascularization,
ositive vessel remodeling, and plaque disruption. More-
ver, there are data to demonstrate that under hypercholes-
erolemic conditions, the vasa vasorum network increases
ramatically, as does the density of macrophages. The
ffects of alcohol on plaque formation and vulnerability are
ot known; however, it is tempting to speculate that by
ncreasing HDL-C or otherwise affecting HDL-C’s multi-
le activities, alcohol may be cardioprotective.
The presence of risk factors such as diabetes mellitus type
, hypercholesterolemia, and smoking exacerbate the pro-
ression of atherosclerotic disease and trigger atherothrom-
otic complications (23,24). These risk factors are all
odified by alcohol. Furthermore, these observations un-
erscore the importance of increased blood thrombosis (BT)rogenase; ALDH  acetaldehyde dehydrogenase; CHD  coronary heart
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June 21, 2005:1916–24 Alcohol and the Cardiovascular Systemn the pathogenesis of vascular diseases. Tissue factor is
ssential to the development of a hyperthrombotic or
rocoagulant state and has been implicated as a risk factor
or the increased rate of atherothrombotic complications
mong diabetic, hyperlipemic, and smoker populations.
ata presented at the workshop indicate that increased BT
eems to be related to plasma levels of a circulating pool of
ctivatable TF activity in diabetics and that hyperlipidemia
nd smoking have a significant modulatory effect on plasma
evels of circulating TF and BT. Monocytes play a critical
ole in modulating TF activity. As an inhibitor of mono-
yte/macrophage activation, alcohol could indirectly de-
rease circulating TF and lessen thrombotic complications;
owever, this remains unproven.
HE GENETICS OF ALCOHOL
ND CARDIOVASCULAR DISEASE
nderstanding the genetic control of alcohol metabolism by
he liver is essential in furthering our explanation of the
echanisms underlying alcohol-induced tissue injury, in-
luding cardiovascular disease. A number of genetic poly-
orphisms controlling alcohol metabolism have been iden-
ified (25). For example, a rapidly metabolizing form of
lcohol dehydrogenase (ADH), the I 2*2 allele, is found in
igher concentrations among many Asian and certain Jew-
sh populations (26). The ADH I 2*2 allele has a Vmax of
pproximately 8.6 compared with the ADH 2*1 allele with
Vmax of 0.23. Alcohol dehydrogenase catalyzes the nico-
inamide adenine dinucleotide (NAD)-dependent oxidation
f ethanol to acetaldehyde. This reaction results in a redox
tate with increased levels of NADH and leads to triglyc-
ride formation. Cytochome P450 2E1, a microsomal
nzyme that is highly inducible by alcohol, also promotes
onversion of ethanol to acetaldehyde. However, this con-
ersion is coupled to the generation of free radicals, reactive
xygen species (ROS), and lipid peroxidation, resulting in
iver and possibly cardiac damage. Genetic variation in the
ctivity of ADH enzymes is the basis for excess acetaldehyde
ccumulation, which causes facial flushing, chest pain, and
rofound hypotension in Asian populations (25). To pre-
ent the unpleasant cardiovascular manifestations of alcohol
ntake, some individuals refrain from drinking. Thus, these
enetic variations provide protection from the medical
onsequences of alcohol by eliciting avoidance behavior.
Acetaldehyde dehydrogenase (ALDH-2) catalyzes the
xidation of acetaldehyde to the less toxic intermediate,
cetate. A defective form, ALDH2*2, is a single allelic
ubstitution ALDH-2 Lys487 that renders the protein
nactive, leading to acetaldehyde accumulation and resulting
oxicities. The relative expression of ADH and ALDH
ontributes to circulating levels of acetaldehyde, a highly
oxic compound with adverse effects on myocardial structure
nd function. Therefore, it is the balance between the levels
f ADH, cytochrome P450 2E1, and ALDH activity that
etermines how much alcohol is handled in the liver and, ronsequently, what byproducts are delivered to peripheral
issues leading to injury.
The clinical phenotype of dilated cardiomyopathy
DCM) is an example of the interplay between genes and
lcohol in the etiology of this disease. In addition to alcohol,
ossible causes include ischemia, infarction, hypertension,
alvular disease, radiation, obesity, diabetes, tachycardia,
nd myocarditis. Early indications of a genetic link in DCM
ere derived from an observational study documenting its
requency in first- and second-degree relatives of patients
iagnosed with idiopathic dilated cardiomyopathy (IDC)
27), which was defined as a left ventricular ejection fraction
50% and left ventricular end-diastolic volume dimension
n the 95th percentile, excluding CAD and other known
auses. Familial dilated cardiomyopathy (FDC) was defined
s having a family member with the same criteria for IDC
s the indexed patient. On that basis, 20% of patients
creened had FDC and approximately 90% of relatives had
nlarged hearts, suggesting that IDC may have a genetic
asis. These findings suggest that FDC exists with a
revalence of 20%; asymptomatic left-ventricular enlarge-
ent may be an early sign of disease.
Similarly, a recent study demonstrating variations in
usceptibility genes and their relation to DCM in chronic
lcoholics found that only a minority of subjects actually
ave DCM, which suggests a genetic vulnerability (28).
ngiotensin-converting enzyme (ACE) genotypes were
ompared among patients having a similar degree of alcohol
ntake with no DCM. In the first group, 41 men were
iagnosed with HF coupled with DCM. The control group
omprised asymptomatic DCM alcoholics who were 53
ears of age with at least 26 to 27 years of heavy alcohol
ntake (167 g/day). In patients with DCM, left ventricular
jection fraction was 34% compared with 67% in control
ubjects. The ACE DD allele, the genotype most common
n subjects with HF, conferred an additional risk and was
resent in 57% of HF subjects compared with control
atients. The difference in allele disposition increased the
isk of HF 16-fold. This observation suggests that the ACE
D allele is associated with alcoholic cardiomyopathy. The
CE genotype data suggest that alcohol may deliver a HF
athway insult. Studies on FDC suggest that alcohol may
eliver an autosomal-dominant pathway insult with incom-
lete penetrance. Therefore, genotyping studies have the
bility to clarify the overall genetic contribution in alcoholic
ardiomyopathies.
In studying the genetics of the response to alcohol, the
mpact of exposure to a moderate amount, where an allele
ay improve the beneficial effect, can be evaluated. How-
ver, that same allele at very high levels of alcohol intake
ay render susceptibility at the tails of the distribution.
sing interindividual variation in the response to treatment
aradigm, the variation in the acute or chronic response to
lcohol can be evaluated. In studying an acute alcohol effect,
he flushing response is a useful quantitative measure of
esponse. A chronic response might focus on changes in the
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Alcohol and the Cardiovascular System June 21, 2005:1916–24isk for developing cardiovascular disease over time. Genetic
olymorphisms specific to alcohol may contribute to differ-
nt aspects of exposure and may influence the response to
arious treatments. Figure 1 is a summary of genes linked
ith alcohol’s effects on the cardiovasculature.
Pharmacogenetics, the study of genetic variables designed
o optimize treatment, can contribute to a better under-
tanding of the cardiovascular outcomes of alcohol con-
umption. The pharmacogenetics of hypertension has sev-
ral corollaries with the biomedical response to alcohol. A
urvey study of hypertensive patients demonstrated that a
ignificant percentage (39%) of the cohort was unaware they
ad the disorder (29). Of those that were aware and being
reated, most were either poorly or not controlled. Thus, the
elationship among awareness, treatment, and control in
ypertension must be taken into account. Similarly, the
harmacogenomics of alcohol can be considered in the
ontext of two major areas of pharmacology. The first
nvolves genes that influence the pharmacokinetics of the
bsorption, distribution, metabolism, and elimination of
lcohol. The second area involves genes that influence the
harmacodynamic interaction between alcohol and its mo-
ecular downstream targets, an interface between alcohol
ntake and cardiovascular disease.
Genetics play an important role in determining factors
nfluencing interindividual variation in response to drug
xposure. Rare adverse outcomes are a single-gene Mende-
ian disorder in which a single-gene mutation renders a
atient susceptible to an adverse outcome once exposure to
drug has occurred. The study of rare outcomes generally is
oncerned with efficacy. Most studies have involved hyper-
ensive or cholesterol-lowering therapies. In terms of alco-
ol, heart disease, and genetics, it is important to define
he question being asked and to design a study that will
nswer the question taking into account variation in short-
ersus long-term alcohol exposure. The field is sufficiently
dvanced for genetics to yield new insight into alcohol
nd CHD.
ECHANISMS UNDERLYING THE
OLECULAR AND CELLULAR EFFECTS OF
LCOHOL ON THE CARDIOVASCULAR SYSTEM
he hemodynamic effects of alcohol consumption have been
ecognized since the middle of the 19th century. Epidemi-
logic studies show that with an average intake of 2
rinks/day, a fairly consistent linear relationship exists
etween alcohol intake and blood pressure in a variety of
opulations, irrespective of race and gender. This relation-
hip is less clear at very low levels of drinking. The
revention And Treatment of Hypertension Study
PATHS), a randomized controlled trial, was undertaken to
etermine among other things, whether blood pressure is
educed by a six-month intervention to lower alcohol intake
n moderate to heavy drinkers with an average duration of
rinking of 37 years (30). Lowering alcohol intake by one to chree drinks/day produced small, nonsignificant effects in
lood pressure in this trial. Larger decreases in alcohol
ntake have been associated with significant reductions in
lood pressure in other clinical trials. A meta-analysis study
hows a net effect that is statistically significant with a
hree–drink/day reduction in alcohol consumption. More
ecently, a reduction by one drink/day in moderate-to-
eavy drinkers led to approximately a millimeter of mercury
eduction in blood pressure (31). Although small, this
eduction represents a substantial improvement in blood
ressure profile overall. This area is one that would benefit
rom additional research.
Sudden cardiac death (SCD) accounts for 60% of
eaths attributable to heart disease in the U.S. today.
entricular arrhythmias are the leading mechanism under-
ying acute and chronic cardiac pathologies, including isch-
mia, myocardial infarction, and cardiomyopathies. How-
ver, aside from anecdotal accounts, there is a dearth of
nformation about the relationship of alcohol to cardiac
rrhythmia and SCD. One study postulated that as many as
% to 50% of SCDs were attributed to alcohol (32). Limited
ata are available on alcohol consumption in most patients
uffering cardiac pathologies; thus, the role of alcohol as a
ofactor is likely to be underestimated. Heavy drinkers have
n increased relative risk of SCD compared with those who
re not heavy drinkers (33). Potential mechanisms that
ould account for these observations are: increased QT
nterval leading to ventricular tachyarrhythmia, electrolyte
bnormalities, sympathoadrenal stimulation, and decreased
agal input. Although alcohol is likely involved in SCD
nder certain circumstances, the multiple pathways involved
nd how signals are transduced into alterations in gene
xpression are not known. Figure 1 summarizes the clinical
anifestations of excessive alcohol on several cardiovascular
utcomes.
Excess alcohol consumption over the course of long
eriods is associated with an increase in oxidative stress,
hich may account for some adverse effects on the cardio-
ascular system. There is evidence that alcohol-induced
ncreases in ROS impair myocyte calcium handling and
echanical function (34). Sources of alcohol-stimulated
OS production have not been fully defined but may
nvolve mitochondrial cytochrome p450, xanthine oxidase,
nd NADPH oxidase (35). In vitro, ROS causes myocyte
ypertrophy, altered gene expression, and apoptosis, raising
he possibility that ROS plays an important role in alcohol-
nduced myocardial remodeling and HF. Although in vitro
tudies may elucidate the role of ROS in mediating the
ffects of alcohol on cardiac myocyte phenotype, studies in
nimal models of alcohol excess will be required to clarify
he role of ROS in myocardial remodeling in vivo. An
nderstanding of the role of ROS in alcoholic cardiomyop-
thy and SCD may suggest new strategies that involve the
se of antioxidants or inhibitors of signaling cascades
ctivated by ROS for the treatment of these prevalent
linical conditions. The effects of alcohol on mitochondrial-
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June 21, 2005:1916–24 Alcohol and the Cardiovascular Systemnduced apoptosis and myocardial remodeling may be me-
iated by affecting the permeability transition pore through
free radical-dependent pathway. During chronic alcohol
xposure, the sensitivity of the mitochondrial membrane to
ermeabilization by calcium and the Bcl-2 family of pro-
eins was increased, resulting in a proapoptotic phenotype.
alcium accumulation in the mitochondria (instead of
eaving the mitochondria through the usual physiological
athways) triggered caspase activation and the apoptotic cell
eath pathway. Low levels of hydrogen peroxide or ROS
ay act as a hypertrophic signaling mechanism in myocytes,
nd higher levels, although not dramatically higher, activate
poptotic signaling pathways.
The vascular endothelium may mediate many of ethanol’s
ffects. The endothelium plays a pivotal role as a sensor,
ransducer, and integrator of signaling processes regulating
ascular homeostasis. Endothelial dysfunction predisposes
o premature clinical events, including CHD, stroke, and
eripheral arterial disease. Few studies have examined the
ole of alcohol as a factor in endothelial dysfunction, yet the
ndothelium is a target for harmful substances such as ROS,
xidized lipoproteins, and advanced glycation end-products.
ecent findings indicate that alcohol directly regulates
ndothelial cell genes involved in inflammation, vessel
atency, and cell adhesion. Treatment with low concentra-
ions of ethanol promotes endothelial cell survival, whereas
poptosis occurs at higher levels (36). The reaction between
uperoxide and nitric oxide (NO) is also germane. Produced
y endothelial cells, NO diffuses to underlying smooth
uscle and causes vasodilatation. The loss of NO that
ccurs in the reaction with superoxide deprives vascular
mooth muscle cells of NO. Additionally, the reaction
roduces the oxidant peroxynitrite, which can lead to
ellular damage. One of the major sources of oxygen-free
adicals is vascular NAD(P)H oxidase. The effect of alcohol
n these and other reactions involving the generation of
OS within the vasculature is unknown. Using newly
eveloped markers of endothelial dysfunction would facili-
ate studies on the effects of alcohol and link changes in
ene expression to functional alterations (37).
Mechanisms proposed to explain the beneficial effects of
oderate alcohol on cardiovascular variables include an
ncrease in HDL-C, favorable effects mediated by alter-
tions in protein kinase C (PKC), and a reduction in the
nflammatory response. High-density lipoprotein choles-
erol is an important factor for maintaining appropriate
oncentrations of LDL-C in vascular and other cells
hroughout the body. Additionally, HDL-C reduces adhe-
ion molecule expression, inhibits oxidation of LDL-C,
educes thrombosis, and inhibits migration of inflammatory
ells into the endothelial space. Acting principally through
polipoprotein (Apo)A1, HDL-C also may have a direct
ntioxidant effect. Moderate alcohol intake is associated
ith an increase in ApoA1, the major HDL-C carrier
rotein. The synthesis and secretion of ApoA1 by humaniver cells and hepatoma cells in culture is stimulated by clcohol. In vivo studies also demonstrate increased transport
ate of ApoA1 and ApoA2 in response to alcohol (38). The
ose effects of ethanol and potential mechanisms of action
re shown in Figure 2.
Protection of myocardial tissue from a lethal ischemic
vent by previous exposure to sublethal ischemic insults has
een termed ischemic preconditioning (39). Epidemiologic
tudies showing that low-to-moderate alcohol consumption
educes CHD raised the possibility that ethanol might
onfer cardiovascular benefit by acting as a preconditioning
gent. Evidence from human and animal studies has sup-
orted this concept. Both acute and chronic moderate
lcohol consumption mimic classic cardiac preconditioning
nd protect against ischemia-reperfusion injury, as evi-
enced by reduced infarct size and decreased hypoxia-
nduced cell death. The mechanism of benefit involves the
KC family of isoforms, particularly PKC- and PKC-,
oth of which are activated by myocardial ischemia.
hereas PKC- aids the myocardium in resisting ischemic
amage, PKC- actually participates in the process of
yocardial damage.
Ethanol shares many of the same signal transduction
athways and effector molecules that have been implicated
n conventional and/or pharmacologic preconditioning. For
xample, just as mitochondrial ATP-sensitive potassium
hannel (KATP) opening has been identified as the putative
ffector of classic cardioprotection, so too are KATP activa-
ion and opening required for ethanol-induced cardiopro-
ection (40). Agents that specifically inhibit opening of
hese KATP channels (41) abrogate ethanol-induced precon-
itioning. Moderate alcohol consumption increases expres-
ion and activation of PKC- and other intracellular kinases
losely linked to cardiac growth and cell survival (42). New
vidence that PKC- is a prime candidate for mediating
lcohol-induced cardioprotection has emerged. PKC-
ntagonists prevent the opening of mitochondrial KATP
igure 2. Dose effects of ethanol consumption and potential mechanisms
f cardiovascular response. CRP  C-reactive protein; HDL-C  high-
ensity lipoprotein cholesterol; ICAM  intercellular adhesion molecule;
L  interleukin; LDL-C  low-density lipoprotein cholesterol; PKC 
rotein kinase C; VCAM  vascular cell adhesion molecule; VEGF 
ascular endothelial growth factor.hannels and abolish cardioprotection. Furthermore,
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ioning and unresponsive to the cardioprotective effect of
lcohol. The diabetic rat is another model in which PKC
as been shown to mediate the beneficial effects of alcohol.
n diabetic animals, alterations in PKC are associated with
decrease in cardiac function as determined by echocardi-
graphy and invasive hemodynamic measurements. Alcohol
onsumption (4% v/v) in diabetic animals prevented the
ecrease in cardiac function and produced an up-regulation
f PKC-, -, and -, similar to levels in nondiabetic
nimals (43).
Other data presented at the workshop bolster the hypoth-
sis that more than one pathway is involved in mediating
ardioprotection. Sphingosine-1-phosphate and ganglioside
M-1 enhance cardiomyocyte protection via a PKC-
ndependent pathway. A better scientific foundation is
eeded to understand the molecular events underlying the
arious forms of preconditioning before this knowledge can
e translated into the development of therapeutic com-
ounds. Whether alcohol is unique in its mode of action or
s a surrogate probe of cardioprotective signaling pathways is
ot known. Studies of how alcohol mediates cellular pro-
ection can uncover innate (homeostatic) cell survival and
epair mechanisms. These observations highlight potential
herapeutic targets for protection against CHD that will not
equire ethanol ingestion, given concerns regarding adverse
ffects of even moderate amounts of alcohol on other organ
ystems and the risk of addiction.
Alcohol is a well-known immunosuppressant involving
oth innate and acquired immune responses (44). It also has
nti-inflammatory properties that are likely mediated
hrough changes in cytokine profiles and cell signaling
athways. Recent data have shown that acute alcohol may
xert beneficial effects on the vascular system by suppressing
roduction of proinflammatory cytokines such as tumor
ecrosis factor-alpha and IL-1 by cells of the immune
ystem (45,46). This reduction in cytokine production is
ssociated with a decrease in phosphorylation of IB,
hich is required for the translocation of NF-kappa-B and
he transcription of proinflammatory cytokines. Alcohol
ncreases macrophage production of IL-10, which has a
trong anti-inflammatory effect. Furthermore, alcohol con-
umption is associated with a decrease in neutrophil migra-
ion and suppression of phagocytosis. Although alcohol has
oth immunosuppressive and anti-inflammatory properties,
ny beneficial effects, for example, on heart and vascular
ndothelium, may be offset by increased susceptibility to
nfections.
RANSLATION: FROM DISCOVERY
O THERAPEUTIC MODALITIES OF TREATMENT
ilated cardiomyopathy and congestive HF are final com-
on consequences of cardiac toxicity caused by numerousnsults, including excessive alcohol exposure (47). Theechanisms by which alcohol causes cardiac damage remain
nknown, but there is emerging evidence implicating oxi-
ative stress, at least in part. Although current HF therapies
ave clinical benefits, none brings about repair or replace-
ent of damaged myocardium. The traditional paradigm of
he heart as a terminally differentiated organ unable to
ndergo repair and regeneration has been modified largely
ecause of the work of Beltrami et al. (48) demonstrating
hat human cardiac myocytes are capable of mitosis after
yocardial infarction. Since then, transplanting progenitor
ells into the heart, a procedure known as cardiomyoplasty,
timulating endogenous precursor cell homing to the heart,
nd myocardial treatment with growth factors involved in
ardiac repair, represent promising new treatment strategies.
mong potential cellular sources used in cardiomyoplasty,
esenchymal stem cells (MSCs) derived from bone marrow
re emerging as a leading candidate. Kraitchman et al. (49)
ave shown in a swine model of myocardial infarction (MI)
hat MSCs can be transplanted by intramyocardial injection
ith robust engraftment and differentiation into a myocyte-
ike phenotype. Neovascularization, improved left-ventricular
unction, and decreased remodeling were observed after the
elivery of MSCs within two weeks of MI. Other cells,
ncluding satellite cells of skeletal muscle origin, also have
een used for cellular cardiomyoplasty. It is tempting to
peculate that cardiac progenitor cells, in addition to their
ole in post-MI repair, may offer a valuable treatment
trategy for toxic and metabolic cardiomyopathies. Panel
embers noted that the study of the effect of alcohol on
ndogenous cardiovascular repair mechanisms and on the
otential of exogenous stem cell-based therapies for cardio-
yopathy is in its infancy. Many of these studies await the
evelopment of better animal models of alcoholic cardio-
yopathy. Ultimately, the goal of such research would be to
ranslate observations regarding the sustained benefits of
oderate alcohol consumption into therapeutic approaches
or protection against CHD that do not require ethanol
ngestion.
UMMARY OF RESEARCH RECOMMENDATIONS
pidemiology of alcohol and cardiovascular disease:
Determine the proportion of reduced CHD risk due to
moderate alcohol consumption not accounted for by
increased HDL-C
Determine the potential benefits of alcohol in individuals
who may be at increased risk (genetic and environmental)
of developing cardiovascular disease
Confirm the influence of beverage type and/or patterns of
drinking on the relationship between alcohol consump-
tion and the risk of developing CHD
Additional studies on the relationship between alcohol
intake and all-cause mortality (given that any protective
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mortality)
enetics of alcohol and cardiovascular disease:
Genotyping studies that define the overall genetic con-
tribution to the development of alcoholic cardiomyopa-
thy and alcohol-induced cardioprotection
Assess the role of genetics in influencing interindividual
variation in the cardiovascular response to alcohol expo-
sure
Characterize the genes involved in susceptibility to car-
diomyopathies and how these are altered by alcohol
Studies on genetic variance of alcoholism and associated
biomedical consequences including cardiovascular disease
Genes influencing the pharmacodynamic interaction be-
tween alcohol and its downstream molecular cardiovas-
cular target
echanisms underlying the molecular and cellular effects of
lcohol:
Gene expression fingerprinting to identify the multiple
pathways associated with alcohol’s effects on the devel-
opment and progression of cardiomyopathies, hyperten-
sion and hemorrhagic stroke
Clarify the role of oxidative stress in alcohol-induced
cardiovascular disease including both local and systemic
effects such as those involving endothelial dysfunction
Studies clarifying the molecular mechanisms underlying
alcohol’s pro- and anti-inflammatory properties; likewise
studies that clarify whether alcohol’s antithrombotic ac-
tion may account for its protective effect
Comprehensive approaches on the effect of alcohol on
atherosclerotic plaque formation, composition, stability,
rupture, thrombotic tendency at the site of vulnerable
plaque, and vessel remodeling; effect of alcohol on
lipoprotein metabolism and HDL-C effector function
Determine whether the cellular targets and molecular
events underlying classic preconditioning are the same or
different than those mediating ethanol-induced cardio-
protection; define the role of mitochondria in alcohol-
induced cardioprotection
ranslation: from discovery to therapeutic modality of
reatment:
Fundamental studies of the effect of alcohol on stem cell
biology and endogenous cardiac repair mechanisms as
well as translational approaches to assess whether exog-
enous stem cell-based therapies are a viable option for
alcohol-induced cardiomyopathies
Translational studies of agents that mimic alcohol’s
protective effects as a potential therapeutic approach to
cardiovascular disease
randomized trial of alcohol intake and cardiovascular
isease prevention. Because of a reluctance to randomly
ssign individuals to alcohol consumption who are naive tolcohol, such a trial would likely be conducted in drinkers
ho are high risk (e.g., postmyocardial infarction) and
andomly assigned to continue moderate drinking or to
bstain. Support for such a study comes from a recent report
f a lower incidence of HF in light-to-moderate drinkers
ith left ventricular dysfunction after MI (50).
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OTE
n the basis of an assessment of the evidence, the National
nstitute on Alcohol Abuse and Alcoholism recently has
ublished a formal position paper on the health risks and
otential benefits of moderate alcohol consumption that
ncludes the area of cardiovascular disease (51).
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